The TRPV4 (transient receptor potential vanilloid 4) ion channel, a member of the vanilloid subfamily of the transient receptor potential channels, is activated by membrane stretch, by non-noxious warm temperatures, and by a range of chemical activators. In the present study we examined the role of phosphorylation in modulating the activation of TRPV4. We expressed TRPV4 in HEK293 cells and activated the channel by cell swelling in a hypotonic solution. TRPV4 channel activation and serine phosphorylation were enhanced by exposure to the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate or by application of bradykinin, which activates PKC via a G-protein-coupled mechanism. The enhancement was inhibited by the PKC inhibitors staurosporine, bisindolylmaleimide I, and rottlerin or by mutation of the serine/threonine residues Ser 162 , Thr 175 , and Ser 189 . The adenylate cyclase activator forskolin also enhanced activation of TRPV4, and the enhancement was antagonized by the selective cyclic AMP-dependent protein kinase (PKA) inhibitor H89 or by mutation of serine residue Ser 824 . Sensitization of TRPV4 by both PKC and PKA depended on the scaffolding protein AKAP79, because channel activation and phosphorylation were enhanced by co-transfection of AKAP79 and were antagonized by removal of AKAP79 using small interfering RNA. We conclude that the serine/threonine kinases PKC and PKA enhance activation of the TRPV4 ion channel by phosphorylation at specific sites and that phosphorylation depends on assembly of PKC and PKA by AKAP79 into a signaling complex with TRPV4.TRPV4 was cloned from kidney, hypothalamus, and auditory epithelium and was given a number of names: OTRPC4 (Osm-9-like TRP channel 4) (1), VR-OAC (2), TRP12 (3), and VRL-2 (vanilloid receptor-like channel 2) (4). The gene for human TRPV4 is located on chromosome 12q23-q24.1 and has 15 exons, which code for a full-length protein with 871 amino acids. TRPV4 is a member of the transient receptor potential vanilloid subfamily of TRP 2 channels, and like other members of this subfamily, it is a polymodal receptor activated by a wide variety of stimuli. TRPV4 is strongly expressed in kidney and is activated by hypotonicity, which has led to the suggestion that TRPV4 is an osmosensor important in regulating body fluid levels (2, 5-9). However, TRPV4 is also activated by innocuous heat with a threshold of Ͼ27°C (6, 10, 11), by the phorbol ester 4␣-phorbol 12,13-didecanoate (12, 13), by low pH (14), by endocannabinoids and arachidonic acid metabolites (15, 16), by the active compound, bisandrographolide A, of Andrographis paniculata, a Chinese herbal plant (17), and by nitric oxide (18). TRPV4 is expressed in a broad range of tissues, including lung, spleen, kidney, testis, fat, brain, cochlea, skin, smooth muscle, liver, and vascular endothelium (1-3); in the lamina terminalis of the mouse brain; in neurons of the arched vascular organ of the lamina terminalis; and in the median preoptic area, the optic chiasm, neurons of the subfornical organ, t...

Epilepsy is a common neurological disorder worldwide and anti-epileptic drugs (AEDs) are always the first choice for treatment. However, more than 50% of patients with epilepsy who take AEDs have reported bone abnormalities. Cytochrome P450 (CYP450) isoenzymes are induced by AEDs, especially the classical AEDs, such as benzodiazepines (BZDs), carbamazepine (CBZ), phenytoin (PT), phenobarbital (PB), and valproic acid (VPA). The induction of CYP450 isoenzymes may cause vitamin D deficiency, hypocalcemia, increased fracture risks, and altered bone turnover, leading to impaired bone mineral density (BMD). Newer AEDs, such as levetiracetam (LEV), oxcarbazepine (OXC), lamotrigine (LTG), topiramate (TPM), gabapentin (GP), and vigabatrin (VB) have broader spectra, and are safer and better tolerated than the classical AEDs. The effects of AEDs on bone health are controversial. This review focuses on the impact of AEDs on growth and bone metabolism and emphasizes the need for caution and timely withdrawal of these medications to avoid serious disabilities.